Why Vivatides Therapeutics’ $54m Series A matters for extrahepatic RNA therapeutics

Vivatides Therapeutics raised $54 million to advance extrahepatic RNA therapeutics. Read why this platform bet could reshape RNA drug development.

Vivatides Therapeutics raised $54 million to advance extrahepatic RNA therapeutics. Read why this platform bet could reshape RNA drug development.